| Title | Author | Year | SCOPUS | PUBMED | ISI | TCI | |
|---|---|---|---|---|---|---|---|
| 1. | Molecular recognition of naphthoquinone-containing compounds against human DNA topoisomerase IIα ATPase domain: A molecular modeling study | Mahalapbutr, P. Wolschann, P. |
2017 | ||||
| 2. | Binding Hotspot and Activation Mechanism of Maltitol and Lactitol toward the Human Sweet Taste Receptor | Mahalapbutr, P. | 2020 | ||||
| 3. | Inhibition of topoisomerase IIα and induction of DNA damage in cholangiocarcinoma cells by altholactone and its halogenated benzoate derivatives | Suksen, K. Mahalapbutr, P. |
2020 | ||||
| 4. | Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases | Mahalapbutr, P. Wolschann, P. |
2020 | ||||
| 5. | In silico screening of chalcones against epstein-barr virus nuclear antigen 1 protein | Mahalapbutr, P. Wolschann, P. |
2020 | ||||
| 6. | Rosmarinic acid as a potent influenza neuraminidase inhibitor: In vitro and in silico study | Mahalapbutr, P. Chamni, S. |
2020 | ||||
| 7. | Structural insight into the recognition of S-adenosyl-L-homocysteine and sinefungin in SARS-CoV-2 Nsp16/Nsp10 RNA cap 2′-O-Methyltransferase | Mahalapbutr, P. | 2020 | ||||
| 8. | The investigation of binary and ternary sulfobutylether-β-cyclodextrin inclusion complexes with asiaticoside in solution and in solid state | Chamni, S. Mahalapbutr, P. |
2020 | ||||
| 9. | Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms | Mahalapbutr, P. | 2020 | ||||
| 10. | Characterization of a nanoparticulate exopolysaccharide from Leuconostoc holzapfelii KM01 and its potential application in drug encapsulation | Mahalapbutr, P. | 2021 | ||||
| 11. | Computational study on peptidomimetic inhibitors against SARS-CoV-2 main protease | Mahalapbutr, P. Hannongbua, S.V. |
2021 | ||||
| 12. | Discovery of novel JAK2 and EGFR inhibitors from a series of thiazole-based chalcone derivatives | Mahalapbutr, P. | 2021 | ||||
| 13. | FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase | Seubwai, W. Sawanyawisuth, K. Obchoei, S. Mahalapbutr, P. Wongkham, S. |
2021 | ||||
| 14. | Identification of vinyl sulfone derivatives as egfr tyrosine kinase inhibitor: In vitro and in silico studies | Mahalapbutr, P. Kuhakarn, C. |
2021 | ||||
| 15. | In Silico Elucidation of Potent Inhibitors and Rational Drug Design against SARS-CoV-2 Papain-like Protease | Sanachai, K. Mahalapbutr, P. Rungrotmongkol, T. Hannongbua, S. |
2021 | ||||
| 16. | In Silico Screening of DNA Gyrase B Potent Flavonoids for the Treatment of Clostridium difficile Infection from PhytoHub Database | Mahalapbutr, P. | 2021 | ||||
| 17. | Lipidomic Analyses Uncover Apoptotic and Inhibitory Effects of Pyrvinium Pamoate on Cholangiocarcinoma Cells via Mitochondrial Membrane Potential Dysfunction | Kittirat, Y. Phetcharaburanin, J. Promraksa, B. Wangwiwatsin, A. Klanrit, P. Sangkhamanon, S. Jarearnrat, A. Thongchot, S. Mahalapbutr, P. Loilome, W. Saya, H. Namwat, N. |
2021 | ||||
| 18. | Molecular basis of the new COVID-19 target neuropilin-1 in complex with SARS-CoV-2 S1 C-end rule peptide and small-molecule antagonists | Mahalapbutr, P. | 2021 | ||||
| 19. | Molecular encapsulation of a key odor-active 2-acetyl-1-pyrroline in aromatic rice with β-cyclodextrin derivatives | Mahalapbutr, P. Hannongbua, S.V. |
2021 | ||||
| 20. | Source of oseltamivir resistance due to single E276D, R292K, and double E276D/R292K mutations in H10N4 influenza neuraminidase | Mahalapbutr, P. | 2021 | ||||
| 21. | Structural dynamics and susceptibility of anti-HIV drugs against HBV reverse transcriptase | Mahalapbutr, P. Wolschann, P. |
2021 | ||||
| 22. | 1′-Acetoxychavicol Acetate from Alpinia galanga Represses Proliferation and Invasion, and Induces Apoptosis via HER2-signaling in Endocrine-Resistant Breast Cancer Cells | Mahalapbutr, P. | 2022 | ||||
| 23. | Allyl ether of mansonone G as a potential anticancer agent for colorectal cancer | Chanvijit, S. Phuagkhaopong, S. Mahalapbutr, P. Klaewkla, M. Chavasiri, W. Wonganan, P. |
2022 | ||||
| 24. | Anserine/Carnosine-Rich Extract from Thai Native Chicken Suppresses Melanogenesis via Activation of ERK Signaling Pathway | Teeravirote, K. Sutthanut, K. Thonsri, U. Mahalapbutr, P. Seubwai, W. Luang, S. Tippayawat, P. Kanthawong, S. Pipattanaboon, C. Duangjinda, M. Chankitisakul, V. Silsirivanit, A. |
2022 | ||||
| 25. | Aurisin A Complexed with 2,6-Di-O-methyl-β-cyclodextrin Enhances Aqueous Solubility, Thermal Stability, and Antiproliferative Activity against Lung Cancer Cells | Charoenwongpaiboon, T. Oo, A. Nasoontorn, S. |
2022 | ||||
| 26. | Discovery of Anilino-1,4-naphthoquinones as Potent EGFR Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Comprehensive Molecular Modeling | Mahalapbutr, P. Leechaisit, R. Thongnum, A. Todsaporn, D. Prachayasittikul, V. Rungrotmongkol, T. Prachayasittikul, S. Ruchirawat, S. Prachayasittikul, V. Pingaew, R. |
2022 | ||||
| 27. | Discovery of JAK2/3 Inhibitors from Quinoxalinone-Containing Compounds | Sanachai, K. Mahalapbutr, P. Tabtimmai, L. Seetaha, S. Kittikool, T. Yotphan, S. Choowongkomon, K. |
2022 | ||||
| 28. | Fisetin glycosides synthesized by cyclodextrin glycosyltransferase from Paenibacillus sp. RB01: characterization, molecular docking, and antioxidant activity | Mahalapbutr, P. | 2022 | ||||
| 29. | Inclusion complexation of emodin with various β-cyclodextrin derivatives: Preparation, characterization, molecular docking, and anticancer activity | Oo, A. Mahalapbutr, P. Krusong, K. Liangsakul, P. Thanasansurapong, S. Reutrakul, V. Kuhakarn, C. Maitarad, P. Silsirivanit, A. Wolschann, P. Putthisen, S. Kerdpol, K. Rungrotmongkol, T. |
2022 | ||||
| 30. | Integration of In Silico Strategies for Drug Repositioning towards P38α Mitogen-Activated Protein Kinase (MAPK) at the Allosteric Site | Suriya, U. Mahalapbutr, P. |
2022 | ||||
| 31. | Low Dose Berberine Suppresses Cholangiocarcinoma Cell Progression as a Multi-Kinase Inhibitor | Obchoei, S. Detarya, M. Boonnate, P. Saranaruk, P. Vaeteewoottacharn, K. Mahalapbutr, P. Wongkham, S. |
2022 | ||||
| 32. | Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma | Suksawat, M. Phetcharaburanin, J. Klanrit, P. Namwat, N. Khuntikeo, N. Titapun, A. Techasen, A. Wangwiwatsin, A. Mahalapbutr, P. Loilome, W. |
2022 | ||||
| 33. | Molecular dynamics simulations of sulfone derivatives in complex with DNA topoisomerase IIα ATPase domain | Mahalapbutr, P. Kuhakarn, C. |
2022 | ||||
| 34. | Molecular encapsulation of emodin with various β-cyclodextrin derivatives: A computational study | Mahalapbutr, P. | 2022 | ||||
| 35. | Multiple actions of NMS-P715, the monopolar spindle 1 (MPS1) mitotic checkpoint inhibitor in liver fluke-associated cholangiocarcinoma cells | Mahalapbutr, P. Vaeteewoottacharn, K. Wongkham, S. Sawanyawisuth, K. |
2022 | ||||
| 36. | Pharmacophore-Based Virtual Screening and Experimental Validation of Pyrazolone-Derived Inhibitors toward Janus Kinases | Sanachai, K. Mahalapbutr, P. Hengphasatporn, K. Shigeta, Y. Seetaha, S. Tabtimmai, L. Langer, T. Wolschann, P. Kittikool, T. Yotphan, S. Choowongkomon, K. |
2022 | ||||
| 37. | Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR | Todsaporn, D. Mahalapbutr, P. Poo-arporn, R.P. Choowongkomon, K. |
2022 | ||||
| 38. | Theoretical studies on RNA recognition by Musashi 1 RNA-binding protein | Darai, N. Mahalapbutr, P. Wolschann, P. Lee, V.S. |
2022 | ||||
| 39. | Unraveling the effect of A143T, P205T and D244N mutations in α-galactosidase A on its catalytic activity and susceptibility to globotriaosylceramide and iminosugar 1-deoxygalactonojirimycin chaperone | Mahalapbutr, P. | 2022 | ||||
| 40. | 3′,4′,5′-trimethoxy- and 3,4-dimethoxychalcones targeting A549 cells: Synthesis, cytotoxic activity, and molecular docking | Danova, A. Nguyen, D.V. |
2023 | ||||
| 41. | BI6727 and GSK461364A, potent PLK1 inhibitors induce G2/M arrest and apoptosis against cholangiocarcinoma cell lines | Riantana, H. Waenphimai, O. Mahalapbutr, P. Karnchanapandh, K. Vaeteewoottacharn, K. Wongkham, S. Sawanyawisuth, K. |
2023 | ||||
| 42. | Daidzein Hydroxylation by CYP81E63 Is Involved in the Biosynthesis of Miroestrol in Pueraria mirifica | Suntichaikamolkul, N. Akashi, T. Mahalapbutr, P. Sanachai, K. |
2023 | ||||
| 43. | Discovery of amphotericin B, an antifungal drug as tyrosinase inhibitor with potent anti-melanogenic activity | Mahalapbutr, P. Sabuakham, S. Nasoontorn, S. |
2023 | ||||
| 44. | Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study | Todsaporn, D. Zubenko, A. Kartsev, V. Aiebchun, T. Mahalapbutr, P. Petrou, A. Geronikaki, A. Divaeva, L. Chekrisheva, V. Yildiz, I. Choowongkomon, K. |
2023 | ||||
| 45. | Discovery of Novel Naphthoquinone-Chalcone Hybrids as Potent FGFR1 Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling | Leechaisit, R. Mahalapbutr, P. Boonsri, P. |
2023 | ||||
| 46. | Enhancing solubility and stability of sorafenib through cyclodextrin-based inclusion complexation: in silico and in vitro studies | Aman, A. Ali, S. Mahalapbutr, P. Krusong, K. Wolschann, P. |
2023 | ||||
| 47. | Improvement of the solubility and anticancer activity of 6,8-dibromochrysin by encapsulation into β-cyclodextrin and its derivatives | Kerdpol, K. Oo, A. Mahalapbutr, P. Todsaporn, D. Phumphuang, S. Chavasiri, W. |
2023 | ||||
| 48. | In Silico and In Vitro Study of Janus Kinases Inhibitors from Naphthoquinones | Sanachai, K. Mahalapbutr, P. Tabtimmai, L. Seetaha, S. Kaekratoke, N. |
2023 | ||||
| 49. | Structural dynamics and susceptibility of isobutylamido thiazolyl resorcinol (ThiamidolTM) against human and mushroom tyrosinases | Mahalapbutr, P. Nuramrum, N. |
2023 | ||||
| 50. | Sulfonylated Indeno[1,2-c]quinoline Derivatives as Potent EGFR Tyrosine Kinase Inhibitors | Hengphasatporn, K. Aiebchun, T. Mahalapbutr, P. Auepattanapong, A. Khaikate, O. Choowongkomon, K. Kuhakarn, C. Meesin, J. Shigeta, Y. |
2023 | ||||
| 51. | Discovery of furopyridine-based compounds as novel inhibitors of Janus kinase 2: In silico and in vitro studies | Suriya, U. Mahalapbutr, P. Geronikaki, A. Kartsev, V. Zubenko, A. Divaeva, L. Chekrisheva, V. Petrou, A. Oopkaew, L. Somngam, P. Choowongkomon, K. |
2024 | ||||
| 52. | Evaluating solubility, stability, and inclusion complexation of oxyresveratrol with various β-cyclodextrin derivatives using advanced computational techniques and experimental validation | Ali, S. Aman, A. Hengphasatporn, K. Oopkaew, L. Todee, B. Fujiki, R. Harada, R. Shigeta, Y. Krusong, K. Choowongkomon, K. Chavasiri, W. Wolschann, P. Mahalapbutr, P. |
2024 | ||||
| 53. | Furopyridine Derivatives as Potent Inhibitors of the Wild Type, L858R/T790M, and L858R/T790M/C797S EGFR | Todsaporn, D. Zubenko, A. Kartsev, V. Mahalapbutr, P. Geronikaki, A. Sirakanyan, S.N. Divaeva, L. Chekrisheva, V. Yildiz, I. Choowongkomon, K. |
2024 | ||||
| 54. | Inclusion complexes of regorafenib with beta- and gamma-cyclodextrin derivatives: In silico and in vitro studies | Aman, A. Ali, S. Oopkaew, L. Mahalapbutr, P. |
2024 | ||||
| 55. | In vitro and in silico studies of the inclusion complexation of 8-bromobaicalein with β-cyclodextrins | Yasuda, N. Ali, S. Aman, A. Krusong, K. Herfindo, N. Chavasiri, W. Choowongkomon, K. Wolschann, P. Mahalapbutr, P. |
2024 | ||||
| 56. | Machine-learning-assisted high-throughput identification of potent and stable neutralizing antibodies against all four dengue virus serotypes | Natsrita, P. Charoenkwan, P. Shoombuatong, W. Mahalapbutr, P. |
2024 | ||||
| 57. | N501Y mutation in SARS-CoV-2 spike RBD protein enhances its binding to ACE2 receptor | Kongtaworn, N. Darai, N. Mahalapbutr, P. Hannongbua, S. Wolschann, P. |
2024 | ||||
| 58. | Novel naphthoquinones as potent aromatase inhibitors: Synthesis, anticancer, and in silico studies | Leechaisit, R. Mahalapbutr, P. Suriya, U. Prachayasittikul, V. Prachayasittikul, S. |
2024 | ||||
| 59. | Correction to: Integration of In Silico Strategies for Drug Repositioning towards P38α Mitogen-Activated Protein Kinase (MAPK) at the Allosteric Site (Pharmaceutics, (2022), 14, 7, (1461), 10.3390/pharmaceutics14071461) | Suriya, U. Mahalapbutr, P. |
2025 | ||||
| 60. | Design, Synthesis, Biological Evaluation and Molecular Modeling Studies of Novel Naphthoquinone-Triazole Hybrids as Potential FGFR1 Tyrosine Kinase Inhibitors | Leechaisit, R. Mahalapbutr, P. Suriya, U. Sukonthasakorn, P. Prachayasittikul, V. Mandi, P. Prachayasittikul, S. |
2025 | ||||
| 61. | Enhancing solubility and stability of piperine using β-cyclodextrin derivatives: computational and experimental investigations | Ali, S. Saokaew, P. Aman, A. Todsaporn, D. Sanachai, K. Krusong, K. Hannongbua, S. Wolschann, P. Mahalapbutr, P. |
2025 | ||||
| 62. | Exploring mimosamycin as a Janus kinase 2 inhibitor: A combined computational and experimental investigation | Sanachai, K. Hengphasatporn, K. Chamni, S. Suwanborirux, K. Mahalapbutr, P. Shigeta, Y. Seetaha, S. Choowongkomon, K. |
2025 | ||||
| 63. | Serum N-Glycomics with Nano-LC-QToF LC-MS/MS Reveals N-Glycan Biomarkers for Glioblastoma, Meningioma, and High-Grade Meningioma | Silsirivanit, A. Alvarez, M.R.S. Grijaldo-Alvarez, S.J. Gogte, R. Kitkhuandee, A. Piyawattanametha, N. Seubwai, W. Luang, S. Panawan, O. Mahalapbutr, P. Vaeteewoottacharn, K. Sawanyawisuth, K. Let-Itthiporn, W. Saengboonmee, C. Duangthongphon, P. Jingjit, K. Pankongsap, A. Waraasawapati, S. Aphivatanasiri, C. Lebrilla, C.B. |
2025 | ||||
| 64. | Synthesis and Biological Assessment of 3',4',5'-Trimethoxychalcone Derivatives against A549 and Molecular Insight Through Molecular Docking and Dynamics Studies | Danova, A. Wonganan, P. Mahalapbutr, P. Maulana, Y.E. Hermawati, E. Mujahidin, D. Chavasiri, W. |
2025 | Count | 64 | 0 | 0 | 0 |
| Title | Authors | Year | Publication name | Cited count | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| < 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | รวม | ||||||
| 1. | Molecular recognition of naphthoquinone-containing compounds against human DNA topoisomerase IIα ATPase domain: A molecular modeling study | Mahalapbutr, P. Wolschann, P. |
2017 |
Journal of Molecular Liquids (247), pp. 374-385 |
||||||||
| 2. | Binding Hotspot and Activation Mechanism of Maltitol and Lactitol toward the Human Sweet Taste Receptor | Mahalapbutr, P. | 2020 |
Journal of Agricultural and Food Chemistry 30 (68), pp. 7974-7983 |
||||||||
| 3. | Inhibition of topoisomerase IIα and induction of DNA damage in cholangiocarcinoma cells by altholactone and its halogenated benzoate derivatives | Suksen, K. Mahalapbutr, P. |
2020 |
Biomedicine and Pharmacotherapy (127), pp. |
||||||||
| 4. | Insights into the Binding Recognition and Susceptibility of Tofacitinib toward Janus Kinases | Mahalapbutr, P. Wolschann, P. |
2020 |
ACS Omega 1 (5), pp. 369-377 |
||||||||
| 5. | In silico screening of chalcones against epstein-barr virus nuclear antigen 1 protein | Mahalapbutr, P. Wolschann, P. |
2020 |
Songklanakarin Journal of Science and Technology 4 (42), pp. 802-810 |
||||||||
| 6. | Rosmarinic acid as a potent influenza neuraminidase inhibitor: In vitro and in silico study | Mahalapbutr, P. Chamni, S. |
2020 |
Current Topics in Medicinal Chemistry 23 (20), pp. 2046-2055 |
||||||||
| 7. | Structural insight into the recognition of S-adenosyl-L-homocysteine and sinefungin in SARS-CoV-2 Nsp16/Nsp10 RNA cap 2′-O-Methyltransferase | Mahalapbutr, P. | 2020 |
Computational and Structural Biotechnology Journal (18), pp. 2757-2765 |
||||||||
| 8. | The investigation of binary and ternary sulfobutylether-β-cyclodextrin inclusion complexes with asiaticoside in solution and in solid state | Chamni, S. Mahalapbutr, P. |
2020 |
Carbohydrate Research (498), pp. |
||||||||
| 9. | Why are lopinavir and ritonavir effective against the newly emerged coronavirus 2019? Atomistic insights into the inhibitory mechanisms | Mahalapbutr, P. | 2020 |
Biochemistry 18 (59), pp. 1769-1779 |
||||||||
| 10. | Characterization of a nanoparticulate exopolysaccharide from Leuconostoc holzapfelii KM01 and its potential application in drug encapsulation | Mahalapbutr, P. | 2021 |
International Journal of Biological Macromolecules (187), pp. 690-698 |
||||||||
| 11. | Computational study on peptidomimetic inhibitors against SARS-CoV-2 main protease | Mahalapbutr, P. Hannongbua, S.V. |
2021 |
Journal of Molecular Liquids (322), pp. |
||||||||
| 12. | Discovery of novel JAK2 and EGFR inhibitors from a series of thiazole-based chalcone derivatives | Mahalapbutr, P. | 2021 |
RSC Medicinal Chemistry 3 (12), pp. 430-438 |
||||||||
| 13. | FOXM1 inhibitor, Siomycin A, synergizes and restores 5-FU cytotoxicity in human cholangiocarcinoma cell lines via targeting thymidylate synthase | Seubwai, W. Sawanyawisuth, K. Obchoei, S. Mahalapbutr, P. Wongkham, S. |
2021 |
Life Sciences (286), pp. |
||||||||
| 14. | Identification of vinyl sulfone derivatives as egfr tyrosine kinase inhibitor: In vitro and in silico studies | Mahalapbutr, P. Kuhakarn, C. |
2021 |
Molecules 8 (26), pp. |
||||||||
| 15. | In Silico Elucidation of Potent Inhibitors and Rational Drug Design against SARS-CoV-2 Papain-like Protease | Sanachai, K. Mahalapbutr, P. Rungrotmongkol, T. Hannongbua, S. |
2021 |
Journal of Physical Chemistry B 50 (125), pp. 13644-13656 |
||||||||
| 16. | In Silico Screening of DNA Gyrase B Potent Flavonoids for the Treatment of Clostridium difficile Infection from PhytoHub Database | Mahalapbutr, P. | 2021 |
Brazilian Archives of Biology and Technology (64), pp. 1-18 |
||||||||
| 17. | Lipidomic Analyses Uncover Apoptotic and Inhibitory Effects of Pyrvinium Pamoate on Cholangiocarcinoma Cells via Mitochondrial Membrane Potential Dysfunction | Kittirat, Y. Phetcharaburanin, J. Promraksa, B. Wangwiwatsin, A. Klanrit, P. Sangkhamanon, S. Jarearnrat, A. Thongchot, S. Mahalapbutr, P. Loilome, W. Saya, H. Namwat, N. |
2021 |
Frontiers in Public Health (9), pp. |
||||||||
| 18. | Molecular basis of the new COVID-19 target neuropilin-1 in complex with SARS-CoV-2 S1 C-end rule peptide and small-molecule antagonists | Mahalapbutr, P. | 2021 |
Journal of Molecular Liquids (335), pp. |
||||||||
| 19. | Molecular encapsulation of a key odor-active 2-acetyl-1-pyrroline in aromatic rice with β-cyclodextrin derivatives | Mahalapbutr, P. Hannongbua, S.V. |
2021 |
Journal of Molecular Liquids (337), pp. |
||||||||
| 20. | Source of oseltamivir resistance due to single E276D, R292K, and double E276D/R292K mutations in H10N4 influenza neuraminidase | Mahalapbutr, P. | 2021 |
Journal of Molecular Liquids (326), pp. |
||||||||
| 21. | Structural dynamics and susceptibility of anti-HIV drugs against HBV reverse transcriptase | Mahalapbutr, P. Wolschann, P. |
2021 |
Journal of Biomolecular Structure and Dynamics 7 (39), pp. 2502-2511 |
||||||||
| 22. | 1′-Acetoxychavicol Acetate from Alpinia galanga Represses Proliferation and Invasion, and Induces Apoptosis via HER2-signaling in Endocrine-Resistant Breast Cancer Cells | Mahalapbutr, P. | 2022 |
Planta Medica 2 (88), pp. 163-178 |
||||||||
| 23. | Allyl ether of mansonone G as a potential anticancer agent for colorectal cancer | Chanvijit, S. Phuagkhaopong, S. Mahalapbutr, P. Klaewkla, M. Chavasiri, W. Wonganan, P. |
2022 |
Scientific Reports 1 (12), pp. |
||||||||
| 24. | Anserine/Carnosine-Rich Extract from Thai Native Chicken Suppresses Melanogenesis via Activation of ERK Signaling Pathway | Teeravirote, K. Sutthanut, K. Thonsri, U. Mahalapbutr, P. Seubwai, W. Luang, S. Tippayawat, P. Kanthawong, S. Pipattanaboon, C. Duangjinda, M. Chankitisakul, V. Silsirivanit, A. |
2022 |
Molecules 21 (27), pp. |
||||||||
| 25. | Aurisin A Complexed with 2,6-Di-O-methyl-β-cyclodextrin Enhances Aqueous Solubility, Thermal Stability, and Antiproliferative Activity against Lung Cancer Cells | Charoenwongpaiboon, T. Oo, A. Nasoontorn, S. |
2022 |
International Journal of Molecular Sciences 17 (23), pp. |
||||||||
| 26. | Discovery of Anilino-1,4-naphthoquinones as Potent EGFR Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Comprehensive Molecular Modeling | Mahalapbutr, P. Leechaisit, R. Thongnum, A. Todsaporn, D. Prachayasittikul, V. Rungrotmongkol, T. Prachayasittikul, S. Ruchirawat, S. Prachayasittikul, V. Pingaew, R. |
2022 |
ACS Omega 21 (7), pp. 17881-17893 |
||||||||
| 27. | Discovery of JAK2/3 Inhibitors from Quinoxalinone-Containing Compounds | Sanachai, K. Mahalapbutr, P. Tabtimmai, L. Seetaha, S. Kittikool, T. Yotphan, S. Choowongkomon, K. |
2022 |
ACS Omega 37 (7), pp. 33587-33598 |
||||||||
| 28. | Fisetin glycosides synthesized by cyclodextrin glycosyltransferase from Paenibacillus sp. RB01: characterization, molecular docking, and antioxidant activity | Mahalapbutr, P. | 2022 |
PeerJ (10), pp. |
||||||||
| 29. | Inclusion complexation of emodin with various β-cyclodextrin derivatives: Preparation, characterization, molecular docking, and anticancer activity | Oo, A. Mahalapbutr, P. Krusong, K. Liangsakul, P. Thanasansurapong, S. Reutrakul, V. Kuhakarn, C. Maitarad, P. Silsirivanit, A. Wolschann, P. Putthisen, S. Kerdpol, K. Rungrotmongkol, T. |
2022 |
Journal of Molecular Liquids (367), pp. |
||||||||
| 30. | Integration of In Silico Strategies for Drug Repositioning towards P38α Mitogen-Activated Protein Kinase (MAPK) at the Allosteric Site | Suriya, U. Mahalapbutr, P. |
2022 |
Pharmaceutics 7 (14), pp. |
||||||||
| 31. | Low Dose Berberine Suppresses Cholangiocarcinoma Cell Progression as a Multi-Kinase Inhibitor | Obchoei, S. Detarya, M. Boonnate, P. Saranaruk, P. Vaeteewoottacharn, K. Mahalapbutr, P. Wongkham, S. |
2022 |
Asian Pacific Journal of Cancer Prevention 10 (23), pp. 3379-3386 |
||||||||
| 32. | Metabolic Phenotyping Predicts Gemcitabine and Cisplatin Chemosensitivity in Patients With Cholangiocarcinoma | Suksawat, M. Phetcharaburanin, J. Klanrit, P. Namwat, N. Khuntikeo, N. Titapun, A. Techasen, A. Wangwiwatsin, A. Mahalapbutr, P. Loilome, W. |
2022 |
Frontiers in Public Health (10), pp. |
||||||||
| 33. | Molecular dynamics simulations of sulfone derivatives in complex with DNA topoisomerase IIα ATPase domain | Mahalapbutr, P. Kuhakarn, C. |
2022 |
Journal of Biomolecular Structure and Dynamics 4 (40), pp. 1692-1701 |
||||||||
| 34. | Molecular encapsulation of emodin with various β-cyclodextrin derivatives: A computational study | Mahalapbutr, P. | 2022 |
Journal of Molecular Liquids (347), pp. |
||||||||
| 35. | Multiple actions of NMS-P715, the monopolar spindle 1 (MPS1) mitotic checkpoint inhibitor in liver fluke-associated cholangiocarcinoma cells | Mahalapbutr, P. Vaeteewoottacharn, K. Wongkham, S. Sawanyawisuth, K. |
2022 |
European Journal of Pharmacology (922), pp. |
||||||||
| 36. | Pharmacophore-Based Virtual Screening and Experimental Validation of Pyrazolone-Derived Inhibitors toward Janus Kinases | Sanachai, K. Mahalapbutr, P. Hengphasatporn, K. Shigeta, Y. Seetaha, S. Tabtimmai, L. Langer, T. Wolschann, P. Kittikool, T. Yotphan, S. Choowongkomon, K. |
2022 |
ACS Omega 37 (7), pp. 33548-33559 |
||||||||
| 37. | Structural dynamics and kinase inhibitory activity of three generations of tyrosine kinase inhibitors against wild-type, L858R/T790M, and L858R/T790M/C797S forms of EGFR | Todsaporn, D. Mahalapbutr, P. Poo-arporn, R.P. Choowongkomon, K. |
2022 |
Computers in Biology and Medicine (147), pp. |
||||||||
| 38. | Theoretical studies on RNA recognition by Musashi 1 RNA-binding protein | Darai, N. Mahalapbutr, P. Wolschann, P. Lee, V.S. |
2022 |
Scientific Reports 1 (12), pp. |
||||||||
| 39. | Unraveling the effect of A143T, P205T and D244N mutations in α-galactosidase A on its catalytic activity and susceptibility to globotriaosylceramide and iminosugar 1-deoxygalactonojirimycin chaperone | Mahalapbutr, P. | 2022 |
Journal of Molecular Liquids (353), pp. |
||||||||
| 40. | 3′,4′,5′-trimethoxy- and 3,4-dimethoxychalcones targeting A549 cells: Synthesis, cytotoxic activity, and molecular docking | Danova, A. Nguyen, D.V. |
2023 |
Journal of Molecular Structure (1275), pp. |
||||||||
| 41. | BI6727 and GSK461364A, potent PLK1 inhibitors induce G2/M arrest and apoptosis against cholangiocarcinoma cell lines | Riantana, H. Waenphimai, O. Mahalapbutr, P. Karnchanapandh, K. Vaeteewoottacharn, K. Wongkham, S. Sawanyawisuth, K. |
2023 |
Pathology Research and Practice (248), pp. |
||||||||
| 42. | Daidzein Hydroxylation by CYP81E63 Is Involved in the Biosynthesis of Miroestrol in Pueraria mirifica | Suntichaikamolkul, N. Akashi, T. Mahalapbutr, P. Sanachai, K. |
2023 |
Plant and Cell Physiology 1 (64), pp. 64-79 |
||||||||
| 43. | Discovery of amphotericin B, an antifungal drug as tyrosinase inhibitor with potent anti-melanogenic activity | Mahalapbutr, P. Sabuakham, S. Nasoontorn, S. |
2023 |
International Journal of Biological Macromolecules (246), pp. |
||||||||
| 44. | Discovery of Novel EGFR Inhibitor Targeting Wild-Type and Mutant Forms of EGFR: In Silico and In Vitro Study | Todsaporn, D. Zubenko, A. Kartsev, V. Aiebchun, T. Mahalapbutr, P. Petrou, A. Geronikaki, A. Divaeva, L. Chekrisheva, V. Yildiz, I. Choowongkomon, K. |
2023 |
Molecules 7 (28), pp. |
||||||||
| 45. | Discovery of Novel Naphthoquinone-Chalcone Hybrids as Potent FGFR1 Tyrosine Kinase Inhibitors: Synthesis, Biological Evaluation, and Molecular Modeling | Leechaisit, R. Mahalapbutr, P. Boonsri, P. |
2023 |
ACS Omega 36 (8), pp. 32593-32605 |
||||||||
| 46. | Enhancing solubility and stability of sorafenib through cyclodextrin-based inclusion complexation: in silico and in vitro studies | Aman, A. Ali, S. Mahalapbutr, P. Krusong, K. Wolschann, P. |
2023 |
RSC Advances 39 (13), pp. 27244-27254 |
||||||||
| 47. | Improvement of the solubility and anticancer activity of 6,8-dibromochrysin by encapsulation into β-cyclodextrin and its derivatives | Kerdpol, K. Oo, A. Mahalapbutr, P. Todsaporn, D. Phumphuang, S. Chavasiri, W. |
2023 |
Journal of the Taiwan Institute of Chemical Engineers (150), pp. |
||||||||
| 48. | In Silico and In Vitro Study of Janus Kinases Inhibitors from Naphthoquinones | Sanachai, K. Mahalapbutr, P. Tabtimmai, L. Seetaha, S. Kaekratoke, N. |
2023 |
Molecules 2 (28), pp. |
||||||||
| 49. | Structural dynamics and susceptibility of isobutylamido thiazolyl resorcinol (Thiamidol<sup>TM</sup>) against human and mushroom tyrosinases | Mahalapbutr, P. Nuramrum, N. |
2023 |
Journal of Biomolecular Structure and Dynamics 21 (41), pp. 11810-11817 |
||||||||
| 50. | Sulfonylated Indeno[1,2-c]quinoline Derivatives as Potent EGFR Tyrosine Kinase Inhibitors | Hengphasatporn, K. Aiebchun, T. Mahalapbutr, P. Auepattanapong, A. Khaikate, O. Choowongkomon, K. Kuhakarn, C. Meesin, J. Shigeta, Y. |
2023 |
ACS Omega 22 (8), pp. 19645-19655 |
||||||||
| 51. | Discovery of furopyridine-based compounds as novel inhibitors of Janus kinase 2: In silico and in vitro studies | Suriya, U. Mahalapbutr, P. Geronikaki, A. Kartsev, V. Zubenko, A. Divaeva, L. Chekrisheva, V. Petrou, A. Oopkaew, L. Somngam, P. Choowongkomon, K. |
2024 |
International Journal of Biological Macromolecules (260), pp. |
||||||||
| 52. | Evaluating solubility, stability, and inclusion complexation of oxyresveratrol with various β-cyclodextrin derivatives using advanced computational techniques and experimental validation | Ali, S. Aman, A. Hengphasatporn, K. Oopkaew, L. Todee, B. Fujiki, R. Harada, R. Shigeta, Y. Krusong, K. Choowongkomon, K. Chavasiri, W. Wolschann, P. Mahalapbutr, P. |
2024 |
Computational Biology and Chemistry (112), pp. |
||||||||
| 53. | Furopyridine Derivatives as Potent Inhibitors of the Wild Type, L858R/T790M, and L858R/T790M/C797S EGFR | Todsaporn, D. Zubenko, A. Kartsev, V. Mahalapbutr, P. Geronikaki, A. Sirakanyan, S.N. Divaeva, L. Chekrisheva, V. Yildiz, I. Choowongkomon, K. |
2024 |
Journal of Physical Chemistry B 50 (128), pp. 12389-12402 |
||||||||
| 54. | Inclusion complexes of regorafenib with beta- and gamma-cyclodextrin derivatives: In silico and in vitro studies | Aman, A. Ali, S. Oopkaew, L. Mahalapbutr, P. |
2024 |
Journal of Molecular Liquids (411), pp. |
||||||||
| 55. | In vitro and in silico studies of the inclusion complexation of 8-bromobaicalein with β-cyclodextrins | Yasuda, N. Ali, S. Aman, A. Krusong, K. Herfindo, N. Chavasiri, W. Choowongkomon, K. Wolschann, P. Mahalapbutr, P. |
2024 |
Journal of Molecular Graphics and Modelling (132), pp. |
||||||||
| 56. | Machine-learning-assisted high-throughput identification of potent and stable neutralizing antibodies against all four dengue virus serotypes | Natsrita, P. Charoenkwan, P. Shoombuatong, W. Mahalapbutr, P. |
2024 |
Scientific Reports 1 (14), pp. |
||||||||
| 57. | N501Y mutation in SARS-CoV-2 spike RBD protein enhances its binding to ACE2 receptor | Kongtaworn, N. Darai, N. Mahalapbutr, P. Hannongbua, S. Wolschann, P. |
2024 |
Asia-Pacific Journal of Science and Technology 2 (29), pp. |
||||||||
| 58. | Novel naphthoquinones as potent aromatase inhibitors: Synthesis, anticancer, and in silico studies | Leechaisit, R. Mahalapbutr, P. Suriya, U. Prachayasittikul, V. Prachayasittikul, S. |
2024 |
Journal of Molecular Structure (1316), pp. |
||||||||
| 59. | Correction to: Integration of In Silico Strategies for Drug Repositioning towards P38α Mitogen-Activated Protein Kinase (MAPK) at the Allosteric Site (Pharmaceutics, (2022), 14, 7, (1461), 10.3390/pharmaceutics14071461) | Suriya, U. Mahalapbutr, P. |
2025 |
Pharmaceutics 4 (17), pp. |
||||||||
| 60. | Design, Synthesis, Biological Evaluation and Molecular Modeling Studies of Novel Naphthoquinone-Triazole Hybrids as Potential FGFR1 Tyrosine Kinase Inhibitors | Leechaisit, R. Mahalapbutr, P. Suriya, U. Sukonthasakorn, P. Prachayasittikul, V. Mandi, P. Prachayasittikul, S. |
2025 |
Asian Journal of Organic Chemistry 5 (14), pp. |
||||||||
| 61. | Enhancing solubility and stability of piperine using β-cyclodextrin derivatives: computational and experimental investigations | Ali, S. Saokaew, P. Aman, A. Todsaporn, D. Sanachai, K. Krusong, K. Hannongbua, S. Wolschann, P. Mahalapbutr, P. |
2025 |
Journal of Biomolecular Structure and Dynamics 5 (43), pp. 2596-2609 |
||||||||
| 62. | Exploring mimosamycin as a Janus kinase 2 inhibitor: A combined computational and experimental investigation | Sanachai, K. Hengphasatporn, K. Chamni, S. Suwanborirux, K. Mahalapbutr, P. Shigeta, Y. Seetaha, S. Choowongkomon, K. |
2025 |
Computational Biology and Chemistry (115), pp. |
||||||||
| 63. | Serum N-Glycomics with Nano-LC-QToF LC-MS/MS Reveals N-Glycan Biomarkers for Glioblastoma, Meningioma, and High-Grade Meningioma | Silsirivanit, A. Alvarez, M.R.S. Grijaldo-Alvarez, S.J. Gogte, R. Kitkhuandee, A. Piyawattanametha, N. Seubwai, W. Luang, S. Panawan, O. Mahalapbutr, P. Vaeteewoottacharn, K. Sawanyawisuth, K. Let-Itthiporn, W. Saengboonmee, C. Duangthongphon, P. Jingjit, K. Pankongsap, A. Waraasawapati, S. Aphivatanasiri, C. Lebrilla, C.B. |
2025 |
Journal of Proteome Research 3 (24), pp. 1402-1413 |
||||||||
| 64. | Synthesis and Biological Assessment of 3',4',5'-Trimethoxychalcone Derivatives against A549 and Molecular Insight Through Molecular Docking and Dynamics Studies | Danova, A. Wonganan, P. Mahalapbutr, P. Maulana, Y.E. Hermawati, E. Mujahidin, D. Chavasiri, W. |
2025 |
Current Medicinal Chemistry (), pp. |
||||||||
| Title | Authors | Year | Journal title |
|---|
| Title | Authors | Year | Journal title | Cited count | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| < 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | รวม | ||||||
| Title | Authors | Year | Journal title |
|---|
| ชื่อโครงการ | Authors | ประเภทโครงการ | ปีงบประมาณ | ทุนวิจับ |
|---|